2-Amino-N-tert-butyl-2-phenyl-acetamide | 112162-59-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Amino-N-tert-butyl-2-phenyl-acetamide
• 英文别名: 2-amino-N-tert-butyl-2-phenylacetamide
• CAS: 112162-59-1
• 化学式: C₁₂H₁₈N₂O
• mdl: MFCD00957573
• 分子量: 206.288
• InChiKey: HYBIFLOQMMPNFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-tert-Butyl-2-phenyl-2-(trimethylsilanyl-amino)-acetamide 在 盐酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以50%的产率得到2-Amino-N-tert-butyl-2-phenyl-acetamide
  参考文献：
  名称：

  Gately, Daniel A.; Norton, Jack R.; Goodson, Patricia A., Journal of the American Chemical Society, 1995, vol. 117, # 3, p. 986 - 995

  摘要：

  DOI：

文献信息

• Carbon Dioxide. A Reagent for the Protection of Nucleophilic Centers and the Simultaneous Activation for Electrophilic Attack. Part 4.¹The α-Substitution of (i) Benzyl Alcohol and (ii) Benzylamine
  作者：Alan R. Katritzky、Wei-Qiang Fan、Kunihiko Akutagawa

  DOI：10.1055/s-1987-27970

  日期：——

  Benzyl alcohol is converted into a variety of α-substituted derivatives by a one-pot sequence involving lithiation of an intermediate hemicarbonate ester. Benzylamine is similarly converted by a one-pot sequence to α-substituted benzylamines: here an intermediate carbamate salt is involved.

  苄醇通过一个一步法序列转化为多种α-取代衍生物，该过程涉及对中间半碳酸酯的锂化。苄胺也通过一个一步法序列转化为α-取代苄胺：在这里，涉及到一个中间的碳酸酯盐。
• Chemokine receptor binding compounds
  申请人：Zhou Yuanxi

  公开号：US20070066624A1

  公开（公告）日：2007-03-22

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及化学因子受体结合化合物、药物组合物及其使用。更具体地，本发明涉及化学因子受体活性调节剂，优选地为CCR4或CCR5的调节剂。在一个方面，这些化合物表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护效应。
• TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS
  申请人：Bertinato Peter

  公开号：US20060223851A1

  公开（公告）日：2006-10-05

  This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R 1 -R 7 , X 1 , m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

  本发明涉及公式（I）中的MTP / Apo-B分泌抑制剂，其中R1-R7，X1，m和n如规范中定义，以及包含该化合物的制药组合物和该化合物和组合物的使用方法。本发明的化合物在治疗肥胖及其相关疾病，情况或障碍方面有用。
• Triamide-substituted heterobicyclic compounds
  申请人：Bertinato Peter

  公开号：US20070093525A1

  公开（公告）日：2007-04-26

  This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R 1 -R 7 , X 1 , m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

  本发明涉及公式(I)中的MTP / Apo-B分泌抑制剂，其中R1-R7，X1，m和n如说明书中所定义，以及包含该化合物的制药组合物，以及使用该化合物和组合物的方法。该发明的化合物对于治疗肥胖症及其相关疾病、病况或障碍具有用途。
• Sulfonamides
  申请人：Crosignani Stefano

  公开号：US20110028509A1

  公开（公告）日：2011-02-03

  The invention relates to compounds of formula I wherein R 1 , R 2 , R 4 , R a , R b , R c , R e , A*, W 1 , W 2 and W 3 are as defined in claim 16 , for the treatment of CXCR3 related diseases.

  该发明涉及式I的化合物，其中R1、R2、R4、Ra、Rb、Rc、Re、A*、W1、W2和W3的定义如权利要求16所述，用于治疗与CXCR3相关的疾病。